Literature DB >> 24633575

Report of successful use of ustekinumab in Crohn's disease refractory to three anti-TNF therapies.

Z S Heetun1, D Keegan, D O'Donoghue, G A Doherty.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633575     DOI: 10.1007/s11845-014-1107-2

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  3 in total

1.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

2.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

3.  Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.

Authors:  Gary P Toedter; Marion Blank; Yinghua Lang; Dion Chen; William J Sandborn; Willem J S de Villiers
Journal:  Am J Gastroenterol       Date:  2009-08-11       Impact factor: 10.864

  3 in total
  1 in total

1.  A preserved stratified pattern of the bowel wall 1 year after major surgery does not influence the surgical recurrence of Crohn's disease.

Authors:  D G Ribaldone; T Cammarota; A Resegotti; M Astegiano
Journal:  Ir J Med Sci       Date:  2015-01-13       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.